Introducing the Erchonia Lunula Laser, the revolutionary low-level laser therapy bringing new hope to people suffering from onychomycosis. Safe and effective, Lunula Laser is the first and only non-thermal laser to receive FDA 510(k) Market Clearance for Onychomycosis. Lunula Laser poses none of the risks and harmful side effects of oral anti-fungal medications and is painless, unlike other laser therapies.
The Erchonia Lunula Laser, uses low level laser light to treat onychomycosis and requires very little time or set-up for physicians or their staff. It’s the only system you can turn on and walk away – the device already has a pre-set protocol. In fact, as little as (4) 12-minute sessions are needed to treat the affected area.*
*Individual results may vary.
Dr. Harris Now Offers
Erchonia's LunulaLaser® for the Treatment of Onychomycosis
FDA-approved, non-thermal, non-invasive, pain-free procedure with new clear nail growth in 6 months
Dr. Harris is now accepting appointments for Erchonia’s new LunulaLaser to target Onychomycosis. The FDA-approved, non-invasive LunulaLaser targets the fungus and stimulate an average of 6.1 mm* new clear nail growth at 6 months.
Dr. Harris comments, “Onychomycosis is a wide spread condition that affects up to 10% of the world’s population. Erchonia’s LunulaLaser is ideal treatment because it offers effective, pain-free, non-thermal treatment—without side effects or dangerous smoke plumes as other hot lasers used to treat onychomycosis. LunulaLaser consists of (4) weekly treatments 12 minute treatments.
Erchonia’s LunulaLaser received FDA-clearance based on a double-blind, randomized, multi-site and placebo-controlled clinical trial. The LunulaLaser clinical trial proved 89% of patients respond to treatment.
Erchonia is the global leader in low level laser healthcare applications. For over two decades Erchonia has been conducting research & development with the world’s leading physicians to advance the science of low level lasers. Erchonia created the low-level laser category after the company was granted the first low level laser FDA clearance for any indication in 2002. Prior to market introduction, all Erchonia lasers are proven to be safe and effective through independent clinical trials. Currently thousands of Erchonia’s lasers are used daily to reduce body fat, treat the appearance of cellulite, target onychomycosis, veterinary applications and eliminate pain. For additional information, visit www.erchonia.com